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Available online 29 March 2016Background: Choosing short-term (3-6 months) or indeﬁnite anticoagulation after a ﬁrst unprovoked venous
thromboembolic event (VTE) is a common and difﬁcult clinical decision. The long-term absolute risk of recurrent
VTE after a ﬁrst unprovokedVTE, in all patients and sub-groups, is notwell established, hindering decisionmaking.
Methods:Weconducted amulti-centermulti-national prospective cohort study inﬁrst unprovokedVTEpatients to
establish the long-term risk of recurrent VTE after short-term anticoagulation in ﬁrst unprovoked VTE patients
(and sub-groups).We followed patients for symptomatic suspected VTE off of OAT. Suspected recurrent VTE was
investigated with reference to baseline imaging and then independently and blindly adjudicated.
Findings:We recruited 663 participants between October, 2001 and March 2006 with the last follow-up in April
2014. During a mean 5.0 years of follow-up, 165/663 suspected VTE (in 408 patients) were adjudicated as recur-
rent VTE resulting in an annualized risk of recurrent VTE of 5.0% (95% CI: 4.2-5.8%) with a cumulative risk of 29.6%
at 8 years. Men had a 7.6% (95% CI: 6.3-9.2%) annual risk of recurrent VTE. High risk women (2 or more HERDOO2
points; see text) had an annual risk of recurrent VTE of 5.9% (95% CI: 4.2-8.1%). Low risk women (1 or 0 HERDOO2
points) had 1.1% (95% CI: 0.6-2.0%) annual risk of recurrent VTE with a cumulative risk of 8.7% at 8 years.
Interpretation:Men and high risk womenwith unprovoked VTE should be considered for long-term anticoagulant
therapy given a high risk of recurrent VTE after long-term follow-up. Women with a low HERDOO2 score may be
able to safely discontinue anticoagulants.
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Venous thromboembolism (VTE) is a common, potentially fatal yet
treatable condition. After 3-6 months of oral anticoagulant therapy
(OAT), the risk of recurrent VTE is variable. Some patient sub-groups
(e.g. post-surgical VTE) have very low annual risk of recurrence (asThe Ottawa Hospital, General
a, K1H 8L6.
. This is an open access article underlow as b1%) [1], in these sub-groups, anticoagulants can be safely
discontinued after 3 months [2]. However, over 50% of patients with
VTE do not have a strong provoking factor [3]. In these unprovoked
VTE patients, the risk of recurrent VTE is substantially higher, reaching
5%-10.8% in the ﬁrst year after stopping 3-6 months of OAT, 5% in the
subsequent year 4 and 2-3% per year thereafter [4–8], with a case fatality
rate for recurrent VTE of 3.6% [9]. OAT is very effective at reducing the
risk of recurrent VTE while on therapy. Vitamin K antagonists reduce
the relative risk of recurrent VTE by N90% [10] and the direct oral anti-
coagulants (dabigatran, apixaban, rivaroxaban) reduce the relative risk
by N80% [10].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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year risk of amajor bleed off of anticoagulant therapy [11,12]with an ad-
ditional increase of as much as 1.3% per year with vitamin K antagonists
and likely less of an increase with direct oral anticoagulants [11]. The es-
timated case fatality rate of major bleed in VTE patients is 11.3% [9].
The literature to date suggests that longer-term anticoagulant thera-
py likely only delays recurrent VTE compared to short-term therapy
[13–15]. Short-term anticoagulant therapy compared to longer-term
therapy randomized trials demonstrated a “catch-up” in recurrent VTE
after completing anticoagulant therapy and, as such, ultimately balanced
long-term risks of recurrent VTE. Hence, the remaining high-priority
clinical question is who should stay on anticoagulants indeﬁnitely and
who can safely discontinue anticoagulants after short term therapy [13,
14]? To answer this important question we must balance the long-
term risk of recurrent VTE, and more importantly, the projected long-
term risk of fatal recurrent VTE, with the projected long-term risk of
major hemorrhage and ultimately fatal major hemorrhage.
A key knowledge gap is that we do not know the long-term risk of
recurrent VTE in patients with a ﬁrst unprovoked VTE and sub-groups
of these patients. To date, only one single center study has published
data on the risk of recurrent VTE in unprovoked VTE patients with a
follow-up time horizon of greater than 3 years [16].
2. Materials and methods
2.1.1. Study Design
Prospective multi-center multi-national cohort study designed to
identify risk factors for recurrent VTE in patients with unprovoked
VTE in long-term follow-up. Initial results on predictors of recurrent
VTE in short-term follow-up (median 18 months) of this cohort have
been previously published [17]. Institutional research ethics board ap-
provalwas obtained at all participating centers and all patients provided
written informed consent prior to participation.
2.1.2. Study Participants/Setting
Consecutive unselected patients at 12 tertiary care centers in 4 coun-
tries were asked to participate if they had: 1) a ﬁrst episode of “unpro-
voked” objectively proven VTE (proximal DVT or PE) 5-7 months prior
to enrollment (herein referred to as the “index VTE”) initially treated
with N5 days of heparin or low molecular weight heparin, followed by
5-7 months of OAT(target INR = 2-3); and 2) no recurrent VTE during
the treatment period. Objective documentation of DVT required a
non-compressible segment on compression leg vein ultrasound imag-
ing in the popliteal vein or a more proximal leg veins. Objectively docu-
mented PE required a high probability V/Q scan or a segmental or larger
artery ﬁlling defect on spiral CT scan. An “unprovoked” index VTE was
deﬁned as VTE occurring in the absence of a leg fracture or lower ex-
tremity plaster cast, immobilization for greater than 3 days, or surgery
using a general anesthetic in the 3 months prior to the index VTE
event, and without the diagnosis of a malignancy in the prior ﬁve
years [18]. We classiﬁed VTE that were solely associated with hormone
replacement therapy or oral contraceptives as “unprovoked”.
Patients were excluded if they were unable or unwilling to provide
written informed consent, were under the age of 18 years, had already
discontinued OAT, required ongoing anticoagulation for reasons other
than VTE, were geographically inaccessible for follow-up, were being
treated for a recurrent unprovoked VTE or had known “high-risk”
thrombophilia (deﬁned as documented deﬁciency of protein S, protein
C or antithrombin, documented persistently positive anticardiolipin an-
tibodies ( N 30U/ml), a documented persistently positive lupus antico-
agulant or 2 or more documented thrombophilic defects (e.g.
homozygous for Factor V Leiden or Prothrombin Gene Mutation, or
compound heterozygous for both)). Thrombophilia testing prior toenrolment was not mandatory per protocol but most patients had
thrombophilia testing performed.
2.1.3. Standardized Baseline Patient Assessment
The baseline assessment took place at 5-7 months after the index
VTE, while patients were still receiving OAT.
The following procedures took place to collect information about po-
tential predictors of recurrent VTE. These predictors were identiﬁed in a
systematic review of the literature conducted a priori and periodically
updated throughout the study (see Appendix I for a detailed list of the
69 independent variables). Note that all procedures were conducted
after 5-7 of OAT therapy following diagnosis of the “index VTE”, and
these were labeled as occurring at “baseline”:
First, clinical datawere collected on demographic characteristics, the
presence of recognizedVTE risk factors at the timeof index VTE, patient-
reported post-thrombotic symptoms, concomitant medications, results
of thrombophilia testing and details of the imaging reports conﬁrming
the index VTE.
Second, study nurses conducted a physical examination for height
and weight, and performed a standardized evaluation for characteristic
signs of the post-thrombotic syndrome (PTS) in both legs [19].
Third, laboratory test sampleswere obtainedwhile the patientwas on
OAT. A complete blood count and homocysteine levels were analyzed at
local clinical laboratories. Standard protocols were used to extract DNA
from peripheral blood leukocytes. An ABI 3100 genetic analyzer (Applied
Biosystems Inc) was used for FVL and PGV genotyping, using established
methods [20]. Samples for factor VIII levels, D-Dimer, lupus anticoagulant,
anticardiolipin IgG/IgM levels were drawn, processed and stored locally,
but shipped on dry ice and analyzed centrally (London Health Sciences
Centre). Within 1 hour of collection, plasma samples were double centri-
fuged at 2500G for 20 minutes and then frozen immediately at -70oC. D-
Dimer testing was conducted using the Vidas® D-Dimer reagent on the
Vidas® Instrument (bioMérieux, Durham, NC, USA). Coagulation assays
were conducted on anACL 9000 instrument (Instrumentation Laboratory
Company, Lexington, MA, USA) with the following reagents: Factor VIII
(HemosIL® APTT-SP reagent), lupus anticoagulant (HemosIL® LAC
screen) and LAC Conﬁrm® reagents (Instrumentation Laboratory Com-
pany, Lexington, MA, USA). Anticardiolipin antibodies (IgG and IgM)
were tested using commercial ELISA kits (Louisville APL Diagnostics,
Inc., Doraville, GA, USA).
Our short-term follow-up cohort study derived a clinical decision
rule, “Men continue and HERDOO2”, whereby men and women with 2
or more of the following are labeled as “high risk of recurrent VTE”:
1) Hyperpigmentation, Edema or Redness in either leg, 2) Vidas D-
Dimer N 250 ug/ml, 3) Obesity with BMI N 30 kg/m2 and 4) Older
than age 65 [17]. Hence, we also explored this multi-variate predictor
score in the current study to determine if the score predicted recurrent
VTE in long-term follow-up.
Finally, baseline imaging was conducted prior to discontinuing OAT
as follows: 1) Compression ultrasound (CUS) leg vein imaging of the
leg(s) that was symptomatic at the time of the index event, and/or
2) Ventilation/perfusion scan if the patient had PE signs or symptoms
at the time of index event. Residual DVT was classiﬁed as ‘yes or no’ as
per Prandoni criteria [21] and ‘percentage obstruction’ as per Piovella
criteria [22]. Pulmonary vascular obstruction (PVO) score was centrally
assigned as previously described [23].
2.1.4. Follow-up and Outcome Assessment
Patients were seen in clinic or telephoned every six months and
asked about any signs/symptoms of DVT or PE. In addition, patients
were instructed to contact study personnel if they developed symptoms
of recurrent VTE at any time during follow-up. Participants were with-
drawn and censored at the time they 1) withdrew consent, 2) were
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umented), were lost to follow-up or 4) died.
All available information about patients who died or who were
suspected of having a recurrent VTE was collected and diagnosis of re-
current VTE independently adjudicated by two physicians who were
blinded to the predictor data. All patients had baseline imaging (5-7
months after initial DVT and/or PE) compared to imaging conducted
at the time of suspected recurrent DVT and/or PE. Patients who present-
ed with leg symptoms underwent compression leg vein ultrasound im-
aging. The criteria used for diagnosis of recurrent DVT were as
previously published [24]. All patients with suspected PE had a V/Q
scan. If the V/Q scan was normal, unchanged or improved compared
with the baseline exam, PE was considered excluded. If the V/Q scan
showed a new mismatched segmental or greater perfusion defect
then PE was diagnosed. If a new matched or sub-segmental perfusion
defect was documented, a CT pulmonary angiogram was performed. If
the CT pulmonary angiogram demonstrated an intraluminal ﬁlling de-
fect in a segmental or larger artery in an area of normal perfusion on
the baseline V/Q scan then PE was diagnosed. PE found at autopsy was
also considered diagnostic of recurrent VTE.
2.1.5. Data Analysis
Univariate analysis (Chi-square test for categorical variables and T-
test for continuous variables) was ﬁrst conducted to determine the
strength of association between each potential predictor variable and
VTE recurrence. Relative risks (RR) and corresponding 95% conﬁdence
intervals (CI) are reported as a measure of univariate association be-
tween potential risk factors and VTE recurrence. We also conducted lo-
gistic regression multi-variate analysis with recurrent VTE as the
dependent variable. We used forward variable selectionwith the stron-
gest univariate and biologically plausible predictors entered ﬁrst. We
also entered biologically plausible interaction terms. All analyses were
conducted with SAS V 9.3 software (SAS institute, Cary, NC, USA).
3. Results
Between October 2001 to March 2006, 664 participants were en-
rolled and 663 completed at least one follow-up (see Fig. 1). Of these,
194 were censored and 165 had recurrent VTE, leaving 304 who com-
pleted 8 years of follow-up event free (see Fig. 1). The mean age of par-
ticipants was 53.2 years (range 18-95), 48.6% were female and the
majority were Caucasian (92%). Index events included 194 (29%) isolat-
ed PE, 346 (52%) isolated DVT and 123 (19%) both DVT and PE. During a
mean follow-up interval of 5.0 years (range 1 month-8 years), 165 of
663 suspected recurrent VTE in 408 patients (with 1 or more episodes
of suspected recurrent VTE) were adjudicated as objectively document-
ed recurrent VTE, for an annualized risk of recurrent VTE of 5.0% (95%CI:
4.2-5.8%). The cumulative risk of recurrent VTE at 8 yearswas 29.6% (see
Fig. 2). Three deaths during follow-up were caused by recurrent VTE
(case fatality rate (3/165)=1.8%, 95% CI: 0.6-5.2%).
In total study population,male genderwas the strongest predictor of
recurrence. Men had a 7.6% (95% CI: 6.3-9.2%) annual risk of recurrent
VTE in mean follow-up of 4.4 years compared to 2.8% (95% CI: 2.2% to
3.7%) in women in a mean follow-up of 5.6 years (RR: 2.7; 95% CI 2.0-
3.7). The next strongest predictor of recurrences was post-thrombotic
syndrome physical exam ﬁndings in either leg (see Table 1). The pres-
ence of hyperpigmentation, edema or redness (HER) on exam in either
leg at the baseline visitwas associatedwith a 36.7% risk of recurrent VTE
compared to 17.8% risk in those without HER (RR 2.1; 95% CI 1.5-2.8).
BMI N30kg/M2, abnormal D-Dimer, FVL, PGV, an abnormal compres-
sion ultrasound or ventilation perfusion scan at 5-7 months after VTE
diagnosis were not predictive of recurrent VTE in the study population
as a whole. (See Table 1.)
Men and high risk women (2 or more HERDOO2 points) had a cu-
mulative 38.5% risk of recurrent VTE at 8 years whereas low riskwomen (1 or 0 HERDOO2 points) had a cumulative risk of recurrent
VTE of 8.7% at 8 years (see Fig. 2; log rank test pb0.0001; HR- 5.7
(95% CI: 3.1-10.2).
Of 322 women, 159 (49.4%) were classiﬁed as low risk (HERDOO2
score of 1 or less). Low riskwomen had a 1.1% (95% CI: 0.6-2.0%) annual
risk of recurrent VTE in a mean follow-up of 6.6 years compared to 5.9%
(95% CI: 4.2-8.1%) in high risk women in a mean follow-up of 4.6 years
(RR 5.2 95% CI 2.7-9.8). Low risk women had a mean age of 42 and only
31% of these women had a hormonally associated VTE (8.8% used hor-
mone replacement therapy and 22.6% used oral contraceptives at the
time of index VTE or in the year prior to index VTE). It is notable that
20/139 high risk women used hormone replacement therapy (n=10)
or used oral contraceptives (n=10) at the time of index VTE or in the
year prior to index VTE. The strongest predictors of recurrences in
women were post-thrombotic syndrome physical exam ﬁndings in ei-
ther leg (see Table 2). The presence of HER on exam in either leg at
the baseline visit was associated with a 6.0% annual risk of recurrent
VTE compared to 1.7% annual risk in women without HER (RR 3.0;
95% CI 1.7-5.1). In addition, D-dimer N 250 ug/l, age N65, FVL and
prior provoked VTE were also predictive of recurrent VTE in women.
In 341 men, the strongest predictors of recurrences were HER in ei-
ther leg (see Table 2).Men with HER had a 10.6% annual risk of recur-
rent VTE compared to a 5.4% annual risk of recurrent VTE in men
without HER (RR 1.7 95% CI: 1.2-2.3).
In multi-variate analysis in the whole study population, male gender
(OR 2.4, 95% CI 1.5-4.1) and HER (1.9, 95% CI 1.2-3.2) were the only inde-
pendent predictors identiﬁed. Non-OO blood group, residual DVT on
baseline CUS, D-Dimer N 250ug/L, FVL, PGV and Age N 65 were not inde-
pendent predictors in thewhole study populationmulti-variatemodel. In
the male sub-group, HER (2.0, 95% CI 1.1-3.5) and hypercholesterolemia
(OR0.3, 95%CI 0.2-0.7)were independent predictors. Non-OOwas not an
independent predictor in the male sub-group. In the female sub-group,
HER (2.8, 95% CI 1.2-6.1), D-dimer N250 ug/ml (3.2, 95% CI 1.4-7.4),
BMIN30 kg/m2 (2.3, 95% CI 1.1-5.1) and non-OO blood group (3.3, 95%
CI 1.2-9.4) were independently predictive of recurrent VTE. Non-OO
and AgeN 65 were not independent predictors in the female sub-group.
4. Discussion
We showed that the long-term risk of recurrent VTE in patients with
unprovoked VTEwas ~30% at 8 years. This represents a substantial bur-
den of recurrent VTE and it is tempting to prescribe highly effective an-
ticoagulant therapy to reduce this burden but the counterbalancing risk
of major bleed must be considered. At this level of long-term risk deci-
sion making about duration of anticoagulation is ambiguous. If the 8
year risk of recurrent VTE is 30% and the case fatality rate of recurrent
VTE is 3.6% we would expect that the projected risk of fatal recurrent
VTEwould be ~1.1% 8 years after discontinuing anticoagulants. Alterna-
tively, if we continue OAT we would anticipate we could reduce the
projected risk of fatal recurrent VTE by N80% to ~ 0.2% but associated
with an incremental projected risk of death from major bleed of 1.1%
(assuming incremental risk of major bleed as high as 1.3% per year for
8 years= 10.4% with case fatality rate of major bleed of 11.3%). Hence,
under reasonable assumptions, there would appear to be no important
projected net mortality beneﬁt from continuing long-term
anticoagulation in unselected patients with unprovoked VTE compared
to discontinuing anticoagulants after short term therapy.
Attention has turned to exploring predictors of recurrent VTE in un-
provoked VTE patients with a hope of identifying high risk and low risk
groups to allow clearer decisionmakingonwho should continue antico-
agulants indeﬁnitely. A number of individual variables that appear to
stratify the risk of recurrent VTE in patients with unprovoked index
VTE have been identiﬁed including gender [25], plasma D-Dimer levels
measured 1-2 months after discontinuation of OAT [26], and residual
venous obstruction using venous US imaging [27,28]. Also clinical deci-
sion tools have been developed and not prospectively validated
Fig. 1. Participant Flow.
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“Men continue and HERDO2 rule [17]”.
In our study, we also showed that the long-term risk of recurrent
VTE after 8 years of follow-up approaches 40% in men and “high risk”
women (womenwith 2 ormore HERDOO2 points). This is an important
ﬁnding. If the 8 year risk of recurrent VTE is 40% and the case fatality rate
of recurrent VTE is 3.6% we would expect that the projected risk of fatal
recurrent VTEwould be 1.4% 8 years after discontinuing anticoagulants.
Alternatively, if we continue OAT we would anticipate we could reduce
the projected risk of fatal recurrent VTE by N80% to less than 0.3% asso-
ciatedwith aworst case scenario cost of an incremental projected risk of
death frommajor bleed of 1.1% (incremental risk of major bleed of 1.3%per year for 8 years= 10.4% with case fatality rate of major bleed of
11.3%). Hence, under reasonable assumptions, we would project a net
mortality beneﬁt from continuing long-term anticoagulation in men
and high risk women compared to discontinuing anticoagulants after
short term therapy.
Conversely, low risk women (1 or less HERDOO2 points) would only
be projected to have a net mortality beneﬁt if the incremental major
bleeding risk on oral anticoagulants was less than 0.3% per year (assum-
ing 9% risk of recurrent VTE with a 3.6% case fatality rate yielding 0.3%
deaths if we discontinue anticoagulants with an alternative of reduction
of recurrent VTE death to 0.06% with continuing OAT at a cost of 2.3% 8
year risk of major bleed with 11.3% case fatality rate). Hence, we can
Fig. 2. Recurrent venous thromboembolism free survival in men and high risk women
(HERDOO2 2 or more points) compared to low risk women (HERDOO2 1 or less points)
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ing anticoagulants.
Post-thrombotic syndrome has been previously suggested to be a
predictor of recurrent VTE in secondary analyses where PTS signs and
symptoms were elicited at varying timepoints [31,32] Given that PTS
may not have had time to develop in patients treated for only 5-7
months after their ﬁrst unprovoked VTE, this ﬁnding may not have ap-
plied to these patients. However, in our study during short term [17]
and long-term follow-up (current study), in which we systematically
collected PTS symptoms and signs at 5-7 months after a ﬁrst unpro-
voked VTE, we found that PTS signs, speciﬁcally HER (Hyperpigmenta-
tion, edema or redness in either leg) were consistently a strong
independent predictor of long-term risk of recurrent VTE in all patientsTable 1
Univariate Analysis of Selected* Predictor Variables in Whole Study Population and Patients w
Predictor Variables Whole Study Pop
% (n/N)
Age (mean) 53.2
Female gender 48.6%
(322/663)
Oral Contraceptive Prior to VTE 7.5%
(50/663)
Hormone Replacement Prior to VTE 3.8%
(25/663)
Leg signs in either leg at baseline visit
Hyperpigmentation 17.4%
(97/558)
Pretibial edema 27.2%
(152/559)
Redness 12.7%
(71/559)
Hyperpigmentation, edema or redness (HER) 39.5%
(221/559)
CUS abnormal 51.3%
(239/465)
V/Q abnormal 59.4%
(186/313)
BMI N 30 Kg/M2:% 37.5% (248/662)
D-Dimer N 250 ug/L 37.6%
(237/631)
Prothrombin gene variant heterozygote or homozygote:% 5.6%
(37/663)
Factor V Leiden heterozygote or homozygote:% 14.7%
(97/659)
Previous secondary VTE:% 4.0% (26/646)
*Predictor variables shownare oneswith strongest association, in the current study,with re
Height (M)2). HRT = Hormone Replacement Therapy. OCP= Oral Contraceptive. CUS = Cwith unprovoked VTE, including patients with isolated PE and gender
sub-groups. It is possible that patients with HER have had prior sub-
clinical or undiagnosed DVT leading to the presence of HER and, as
such, are at higher risk of risk of overt recurrent VTE in the long-term.
The strengths of our study include that our patient population was
homogeneous (we only included symptomatic major VTE (i.e. excluded
distal DVT and sub-segmental PE) patients treated with short anticoag-
ulant therapy (5-7 months)). We collected a fulsome set of potential
predictors that were determined apriori and collected in a standardized
manner without knowledge of the outcome. We had minimal loss to
follow-up over a prolonged period of follow-up (6.6% over 8 years).
We recruited patients in multiple centers in multiple countries
strengthening the generalizability of our ﬁndings. All of our outcomes
were symptomatic, objectively documented and independently adjudi-
cated with comparison to baseline imaging. The latter may explain why
we documented a lower rate of recurrent VTE compared to the single
center Italian study [16]where the absence of baseline imaging may
have led to over-diagnosis of recurrent VTE [33].
There are some limitations to our work. While the risk beneﬁt bal-
ance appears to favor continuing anticoagulants in men and high risk
women if one considers an 8 year time-horizon it remains unknown if
we would draw the same conclusion over an even longer time-
horizon. The “Men continue andHERDOO2” requires validation in a sec-
ond cohort study prior to widespread adoption as per current clinical
decision rule methods guidelines [34]. Patients with known “high risk”
thrombophilia were excluded hence our ﬁndings may not apply to
these patients.
In conclusion, the long-term cumulative risk of recurrent VTE in pa-
tients with a ﬁrst unprovoked VTE who have completed short term an-
ticoagulants (5-7 months) is substantial (~30% at 8 years) but it is
unclear if anticoagulants would provide a projected net mortality bene-
ﬁt in these patients. In low risk patients (1 or 0 HERDOO2 points), the
cumulative risk of recurrent VTE is low and it is unlikely that these pa-
tients would beneﬁt from indeﬁnite anticoagulant therapy.ith and without Recurrent VTE during Long-Term Follow-up
ulation Recurrent
VTE (rVTE)
No Recurrent
VTE (no rVTE)
P-value
53.1 53.2 0.92
31.5%
(52/165)
54.2%
(270/498)
b0.0001
2.4%
(4/165)
9.2%
(46/498)
0.002
3.0%
(3/165)
4.0%)
(20/498)
0.38
24.8%
(35/141)
14.9%
(62/417)
0.007
47.5%
(67/141)
20.3%
(85/418)
b0.0001
19.9%
(28/141)
10.3%
(43/418)
0.003
57.4%
(81/141)
33.5%
(140/418)
b0.0001
57.4%
(81/141)
48.7%
(158/324)
0.09
63.1%
(41/65)
58.5%
(145/248)
0.50
39.4% (65/165) 36.8% (183/497) 0.554
42.8%
(68/159)
35.8%
(169/472)
0.1169
3.6%
(6/165)
6.2%
(31/498)
0.14
18.3% (30/164) 13.5% (67/495) 0.13
5.5% (5/91) 3.8% (21/555) 0.39
current VTE.VTE=Venous thromboembolism. BMI=BodyMass Index (Weight (kg)/
ompression Ultrasound Leg Vein Imaging. V/Q Scan = Ventilation Perfusion Scan.
Table 2
Univariate Analysis and Relative Risks of Predictor Variables in Gender Sub-Groups.
Variable↓
(n/N)
% with recurrent VTE if
variable present (n/N)
% with recurrent VTE if
variable absent (n/N)
P-Value Relative Risks
(95% CI:L - U)
MALES
Hypercholesterolemia
(73/341)
20.6%
(15/73)
36.6%
(98/268) 0.01 0.6 (0.3-0.9)
Leg signs in either leg at baseline visit
Pretibial edema
(80/293)
50.0%
(40/80)
25.3%
(54/213) b0.0001 2.0 (1.4 – 2.7)
Hyperpigmentation
(60/292)
38.3%
(23/60)
30.6%
(71/232) 0.25 1.3 (0.9 – 1.8)
Redness
(37/293)
40.5%
(15/37)
30.8%
(79/256) 0.23 1.3 (0. 9– 2.0)
Hyperpigmentation, edema or redness
(122/293)
41.8%
(51/122)
25.1%
(43/171) 0.003 1.7 (1.2-2.3)
Other predictor variables
Factor V Leiden
(44/340)
34.1%
(15/44)
32.7%
(97/296) 0.86 1.0 (0.7 - 1.6)
BMI over 30
(133/341) 30.8% (41/133) 34.6% (72/208) 0.468 0.9 (0.6 - 1.2)
D-Dimer over 250ug/L
(110/321) 33.6% (37/110) 34.1% (72/211) 0.93 0.9 (0.7 - 1.4)
Previous, secondary VTE
(14/341) 14.3% (2/14) 33.9% (111/327) 0.155 0.4 (0.1 - 1.5)
FEMALES
Leg signs in either leg at baseline visit
Hyperpigmentation (37/266)
32.4%
(12/37)
15.3%
(35/229) 0.01 2.1 (1.2 – 3.7)
Pretibial edema
(72/266)
37.5%
(27/72)
10.3%
(20/194) b0.0001 3.6 (2.2 – 6.1)
Redness
(34/266)
38.2%
(13/34)
14.6%
(34/232) 0.0008 2.6 (1.5 – 4.4)
Hyperpigmentation, edema or redness (99/266)
30.3%
(30/99)
10.2%
(17/167) b0.0001 2.9 (1.7-5.1)
Other predictor variables
D_dimer over 250ug/L
(127/310) correct 24.4% (31/127) 10.4% (19/183) 0.001 2.4 (1.4 - 4.0)
BMI over 30
(115/321) correct 20.9% (24/115) 13.6% (28/206) 0.0897 1.5 (0.9 - 2.5)
Age over 65
(91/322) correct
25.3%
(23/91) 12.6% (29/231) 0.0052 2.0 (1.2 - 3.3)
Previous, secondary VTE
(14/322)
35.7%
(5/14)
15.3%
(47/308) 0.04 2.3 (1.1 - 4.9)
Factor V Leiden
(53/319)
28.3%
(15/53)
13.9%
(37/266) 0.01 2.0 (1.2 - 3.4)
95% CI:L, U = 95% Conﬁdence Interval : Lower limit and Upper limit. ACL = Anticardiolipin antibody. LAC = Lupus Anticoagulant. FVIII = Factor VIII level. BMI = Body Mass Index
(Weight(kg)/Height(M) [2]). ASA = Aspirin. VTE= Venous thromboembolism. HRT = Hormone Replacement Therapy. OCP = Oral Contraceptive.
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Appendix I
We collected the following information at the time of enrollment:
1) Demographic variables: age, gender, ethnic background (partici-
pant’s selection of ethnicity) given variable rates of thrombophilia in
different ethnicities, socioeconomic status, height, weight and BMI,
2) Risk factors for index VTE: immobilization, surgery, low extremity
fracture, stroke, myocardial infarction, hormone replacement, oral con-
traceptive use, malignancy, varicose veins, trauma, pregnancy or 6
weeks postpartum, family history of VTE, previous secondary VTE,
known thrombophilias (Protein C, S or AT deﬁciency, antiphospholipid
antibody syndrome, hyperhomocysteinemia, Factor V Leiden and Pro-
thrombin gene mutation), statin use, known hypercholesterolemia,
3) Concomitantmedications, 4) Compression stocking use, 5) Laborato-
ry data: Factor V Leiden, Prothrombin Gene Mutation, Hemoglobin,
Platelets, C-reactive protein, Homocysteine, Factor VIII, D-Dimer,
Lupus anticoagulant, Anticardiolipin IgG, Anticardiolipin IgM, INR and
aPTT, 6) Imaging: Ventilation Perfusion Scan (V/Q) (residual PE was
classiﬁed as ‘yes or no’ and the pulmonary vascular obstruction (PVO)
score was calculated [23] and compression ultrasound of legs with
symptoms or signs of DVT at the time of index event (residual DVT
was classiﬁed as ‘yes or no’ as per Prandoni criteria [21] and ‘percentage
obstruction’ as per Piovella criteria [22] and 7) Post-thrombotic syn-
drome: Symptoms in either leg of cramps, itching, pins and needles,
pain or swelling and signs in either leg of pretibial edema, skin indura-
tion, hyperpigmentation, venous ectasia, redness, pain during calf com-
pression, warmth, dependent cyanosis or leg ulcers and leg
circumference.
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